References
- Tait RJ, Caldicott D, Mountain D, et al. A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment. Clin Toxicol. 2016;54:1–13.
- Chase PB, Hawkins J, Mosier J, et al. Differential physiological and behavioral cues observed in individuals smoking botanical marijuana versus synthetic cannabinoid drugs. Clin Toxicol. 2016;54:14–19.
- Ford LT, Berg JD. 1-Adamantylamine a simple urine marker for screening for third generation adamantyl-type synthetic cannabinoids by UPLC-MS/MS. Ann Clin Biochem. 2016. [Epub ahead of print]. doi: 10.1177/0004563216628892.
- Pertwee RG. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Pharmacol Ther. 1997;74:129–180.
- Castaneto MS, Gorelick DA, Desrosiers NA, et al. Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend. 2014;144:12–41.
- Castaneto MS, Scheidweiler KB, Gandhi A, et al. Quantitative urine confirmatory testing for synthetic cannabinoids in randomly collected urine specimens. Drug Test Anal. 2015;7:483–493.
- Sharma P, Murthy P, Bharath MM. Chemistry, metabolism, and toxicology of cannabis: clinical implications. Iran J Psychiatry. 2012;7:149–156.
- Fantegrossi WE, Moran JH, Radominska-Pandya A, et al. Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to D9-THC: mechanism underlying greater toxicity? Life Sci. 2014;97:45–54.
- Lu D, Meng Z, Thakur GA, et al. Adamantyl cannabinoids: a novel class of cannabinergic ligands. J Med Chem. 2005;48:4576–4585.
- McIlroy G, Ford L, Khan JM. Acute myocardial infarction, associated with the use of a synthetic adamantyl-cannabinoid: a case report. BMC Pharmacol Toxicol. 2016;17:2
- Tse R, Kodur S, Squires B, et al. Sudden cardiac death complicating acute myocardial infarction following synthetic cannabinoid use. Intern Med J. 2014;44:934–936.
- Ibrahim S, Al-Saffar F, Wannenburg T. A unique case of cardiac arrest following K2 abuse. Case Rep Cardiol. 2014;2014:120607.
- McKeever RG, Vearrier D, Jacobs D, et al. K2-Not the spice of life; synthetic cannabinoids and ST elevation myocardial infarction: a case report. J Med Toxicol. 2015;11:129–131.
- Monte AA, Bronstein AC, Cao DJ, et al. An outbreak of exposure to a novel synthetic cannabinoid. N Engl J Med. 2014;370:389–390.